-

Dexcom Canada Achieves Great Place to Work® Certification for Second Consecutive Year

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that for the second consecutive year, it has been certified as a Great Place to Work® in Canada for 2023-24. Awarded by Great Place to Work Institute®, the global authority on workplace culture, this certification is based on direct feedback from employees about their workplace experience, and the sentiment of pride they feel in representing Dexcom.

“Being recognized as a Great Place to Work in Canada for the second year in a row is a great achievement,” says André Côté, Vice President, General Manager at Dexcom Canada. “Dexcom has always been a purpose-driven company and it’s clear that our employees share that passion for the work that we do, in helping to empower people with diabetes to take control of their health. Many of our staff are personally affected by diabetes or have family members with diabetes, so their work at Dexcom is more than just a job. This certification would not be possible without their heart and dedication to their work and our mission as a company.”

Through the Great Place to Work® survey, Dexcom Canada employees awarded the organization high marks in areas such as supporting work-life balance and providing a psychologically and emotionally healthy place to work. The survey also revealed that Dexcom staff take pride in representing a company that helps those living with diabetes live a healthy, full life.

“We owe our success as a company to our team, for their ongoing efforts in creating and maintaining a positive environment, living our values, and showing up every day in a spirit of service. While we are honoured to be named a Great Place to Work® in Canada for the second time, we are always working to make our company a place where everyone feels like they can be themselves, which is also critical to making a meaningful impact in our community,” says Iris Nikolic, HR Business Partner.

Dexcom Canada continues to expand its presence across Canada and bring life-changing diabetes management technology to more Canadians. Visit Dexcom’s Careers page to learn more about available opportunities to join our growing team.

About Dexcom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

About Great Place to Work®

Great Place to Work is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, Great Place to Work recognizes Canada’s Best Workplaces in a series of national lists including those published by The Globe & Mail (Canada) and Fortune magazine (USA). Great Place to Work provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. Visit us at www.greatplacetowork.ca or find us on Twitter at @GPTW_Canada.

Contacts

Laura Andrejicka, 519.560.7860
Veritas Communications
andrejicka@veritasinc.com

Dexcom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Laura Andrejicka, 519.560.7860
Veritas Communications
andrejicka@veritasinc.com

More News From Dexcom, Inc.

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...
Back to Newsroom